Adrenal Cortex Tumors and Hyperplasias

    November 2011 in “ InTech eBooks
    Duarte Pignatelli
    Image of study
    TLDR Most adrenal cortex tumors are benign and non-secreting, but proper diagnosis and treatment are important due to the rare possibility of cancer.
    The document from 2011 provides a comprehensive overview of adrenal cortex tumors and hyperplasias, including benign adrenocortical tumors (ACTs), malignant adrenal cortex cancers (ACCs), and various hyperplasias. It notes that most ACTs are non-secreting and benign, found in at least 3% of adults over 50, while ACCs are rare with an incidence of 1-2 cases per million per year. The Weiss system is used to differentiate between adenoma and carcinoma, with malignancy indicated by meeting 4 or more criteria. The pathogenesis of ACC involves uncontrolled cell proliferation and genomic instability, with IGF-II overexpression observed in ACC. Genetic aspects such as TP53 mutations and Wnt signaling pathway involvement are discussed, with ß-catenin mutations common in adenomas. Clinically, 50-60% of ACCs are functional, causing hormonal syndromes. Imaging studies are crucial for tumor differentiation, and tumor size is a strong malignancy indicator. The document also addresses primary aldosteronism, androgen and estrogen-secreting tumors, Cushing's syndrome, and incidentalomas, emphasizing the importance of distinguishing between benign and malignant tumors for appropriate treatment. Pediatric adrenal cortex tumors and ACTH-independent hyperplasias are covered, with genetic mutations in the cyclic AMP pathway contributing to these conditions. Lastly, the document discusses AIMAH and ACTH-independent micronodular hyperplasias, including genetic mutations and clinical presentations, with bilateral adrenalectomy often being the treatment. The document does not provide specific study sizes, limiting the assessment of the strength of the studies mentioned.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    6 / 60 results

      community Now i want to see if this DHT survives

      in Treatment  33 upvotes 1 week ago
      The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  9 upvotes 1 week ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community My personal thoughts on DHT. belive it or not

      in Research/Science 7 months ago
      The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

      community Mechanism of action of alfatradiol (17 alpha estradiol)

      in Research/Science  6 upvotes 1 year ago
      The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

      community 11-month update. This time wet hair comparison!

      in Progress Pictures  108 upvotes 1 year ago
      The post discusses an 11-month hair loss treatment journey using dutasteride, minoxidil, nizoral, and 1.5mm derma rolling. The responses inquire about the frequency of derma rolling and express optimism for further progress.

    Similar Research

    5 / 1000+ results